A Comprehensive Review of the Role of Biologics and Small-Molecule Therapies in the Long-Term Management of Crohn's Disease.

Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract, poses significant therapeutic challenges due to its relapsing course and complex pathophysiology. With the rapid expansion of biologic agents and small-molecule therapies, clinicians face increasing complexity in selecting and sequencing treatment options. To address this, we conducted an extensive literature review across various databases, including PubMed and Google Scholar, focusing on studies published within the last decade. Inclusion criteria encompassed randomized controlled trials, cohort studies, and narrative reviews that evaluated adult and middle-aged populations. Case reports, non-peer-reviewed sources, and studies with limited follow-up data were excluded from the analysis. This review examines the mechanisms of action, clinical efficacy, safety profiles, and treatment positioning of biologic agents, such as anti-TNF therapies, anti-integrins, and IL-12/23 inhibitors, as well as small-molecule therapies, including JAK inhibitors and S1P receptor modulators. We also explore emerging strategies such as early biologic initiation, combination regimens, and personalized approaches to therapy. Upon evaluating statistical data from the included studies, we conclude that biologics and small-molecule therapies currently constitute the cornerstone of long-term management in moderate to severe CD. This review aims to synthesize contemporary clinical evidence and provide insights into future therapeutic directions.